Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company has announced that its wholly-owned subsidiary, Alaska Acquisition, has commenced its tender offer for all outstanding shares of ImClone Systems at a price of $70 net per share in cash.
Subscribe to our email newsletter
Lilly and ImClone have previously announced that they had reached a definitive merger agreement for Lilly to acquire ImClone. There is no financing condition to the tender offer.
The tender offer is subject to certain conditions, including a minimum share tender condition, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other governmental approvals.
Unless the tender offer is extended, the tender offer and any withdrawal rights to which ImClone’s shareholders may be entitled will expire on November 20, 2008. Following the acceptance for payment of shares in the tender offer and completion of the transactions contemplated in the merger agreement, ImClone will become a wholly-owned subsidiary of Lilly.